What is Zacks Research’s Estimate for WST FY2027 Earnings?

West Pharmaceutical Services, Inc. (NYSE:WST) – Analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of West Pharmaceutical Services in a report released on Thursday, March 6th. Zacks Research analyst I. Bandyopadhyay anticipates that the medical instruments supplier will earn $8.18 per share for the year. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share.

A number of other research analysts have also commented on the company. Citigroup assumed coverage on West Pharmaceutical Services in a report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price objective on the stock. UBS Group upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and raised their target price for the stock from $350.00 to $390.00 in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a research report on Friday, February 14th. Bank of America raised their price target on West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a report on Friday, December 13th. Finally, StockNews.com cut West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and a consensus target price of $344.00.

West Pharmaceutical Services Stock Up 0.8 %

Shares of West Pharmaceutical Services stock opened at $232.37 on Friday. The stock has a 50-day moving average price of $299.44 and a 200 day moving average price of $306.81. The company has a market cap of $16.80 billion, a P/E ratio of 34.73, a P/E/G ratio of 6.74 and a beta of 1.09. The company has a current ratio of 2.79, a quick ratio of 2.23 and a debt-to-equity ratio of 0.08. West Pharmaceutical Services has a 1 year low of $197.01 and a 1 year high of $400.88.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.07. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The company had revenue of $748.80 million during the quarter, compared to analysts’ expectations of $739.59 million.

Hedge Funds Weigh In On West Pharmaceutical Services

Several institutional investors and hedge funds have recently made changes to their positions in the company. Quadrant Capital Group LLC grew its position in shares of West Pharmaceutical Services by 5.4% in the fourth quarter. Quadrant Capital Group LLC now owns 626 shares of the medical instruments supplier’s stock valued at $205,000 after purchasing an additional 32 shares during the last quarter. Baron Wealth Management LLC grew its position in shares of West Pharmaceutical Services by 1.9% in the fourth quarter. Baron Wealth Management LLC now owns 1,926 shares of the medical instruments supplier’s stock valued at $631,000 after purchasing an additional 35 shares during the last quarter. Exchange Traded Concepts LLC grew its position in shares of West Pharmaceutical Services by 18.9% in the fourth quarter. Exchange Traded Concepts LLC now owns 239 shares of the medical instruments supplier’s stock valued at $78,000 after purchasing an additional 38 shares during the last quarter. Lake Street Advisors Group LLC grew its position in shares of West Pharmaceutical Services by 5.8% in the fourth quarter. Lake Street Advisors Group LLC now owns 711 shares of the medical instruments supplier’s stock valued at $233,000 after purchasing an additional 39 shares during the last quarter. Finally, Covestor Ltd grew its position in shares of West Pharmaceutical Services by 14.3% in the third quarter. Covestor Ltd now owns 320 shares of the medical instruments supplier’s stock valued at $96,000 after purchasing an additional 40 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.36%. The ex-dividend date is Wednesday, April 30th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.56%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.